Over the years, the FDA has published several highly targeted series of iterations on formal PDUFA interactions, beginning with foundational frameworks under FDAMA in 2000, progressing through major updates in 2017 and 2018, and evolving into draft revisions in late 2023. The latest guidance released this week discusses important procedural and logistical preferences of the Agency. Rather than completely rewriting the playbook, this document codifies lessons learned from the virtual meeting era and streamlines communication channels between sponsors and regulatory review teams. Understanding how this text refines previous iterations reveals key operational shifts that affect every drug development pipeline.
The first striking addition is the formal integration and expansion of two specialized meeting categories: Type D meetings and INTERACT meetings. In older historical guidance iterations, sponsors were largely constrained to broad Type A, B, and C meetings. Under this guidance, Type D meetings cater to narrow, highly specific decision points, restricted to no more than two focused topics across three or fewer review disciplines, offering rapid 50-day turnarounds. Meanwhile, INTERACT meetings are specifically structured for novel early-stage products facing unique development hurdles prior to a pre-IND meeting. These specialized options allow sponsors to resolve targeted technical bottlenecks rapidly without resorting to bulky Type C requests.
The second critical operational change is the hard limit on meeting queries. To prevent sponsors from overloading meeting requests with exhaustive lists of sub-queries, the FDA now explicitly recommends a maximum of 10 total questions (including all sub-questions) per meeting request and briefing package. Furthermore, the guidance institutes a strict, sequential numbering rule, requiring sub-parts to be numbered sequentially (e.g., 1, 2, 3) rather than nested under letters (e.g., 1a, 1b, 1c). This rule forces sponsors to sharpen their scientific focus, prioritize essential regulatory questions, and eliminate filler topics before approaching review divisions.
Third, the guidance reflects a permanent modernization of meeting formats by defining Hybrid In-Person (HIP) face-to-face meetings alongside Virtual Face-to-Face (video conferencing), Teleconferences, and Written Response Only (WRO) paths. Under the HIP model, core representatives from both the sponsor and the FDA participate in person at Agency headquarters, while non-core participants join virtually. Crucially, the guidance grants the FDA broad discretion to convert requested meeting formats, such as pre-IND, Type C, Type D, and INTERACT requests, into WRO formats if the Agency determines written feedback is sufficient. This gives review divisions greater administrative flexibility to manage workload while still delivering binding preliminary responses.
Ultimately, this guidance establishes a more structured, precise, and efficient framework for sponsor-agency interactions under PDUFA VII. These are not new policies but formalization of practices that have been in effect over the last few years. By capping question counts, defining clear meeting formats, and formalizing rapid-turnaround engagement types, the FDA is signaling that clarity and brevity are the gold standards for regulatory communication. Sponsors who align early with these procedural boundaries will secure quicker feedback, eliminate unnecessary submission delays, and maintain maximum momentum toward key clinical milestones.
